Antibody drug conjugates: Development, characterization, and regulatory considerations

Nagavendra Kommineni, Palpandi Pandi, Naveen Chella, Abraham J. Domb, Wahid Khan

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Previously, cancer chemotherapy was often accompanied by severe side effects. Antibody drug conjugates (ADCs) were introduced to address this treatment complication. ADCs are a potent category of bioconjugates and immunoconjugates designed as targeted therapy for the treatment of cancer. ADCs are complex molecules composed of an antibody linked via linker chemistry to a cytotoxic payload or drug. Therefore, biologic properties of the cell-surface target antigen are important in designing an effective ADC as an anticancer agent. ADCs have the ability to discriminate between the healthy and diseased tissue, so that healthy cells are less effected and get maximum therapeutic benefit. This review describes the development, characterization, and regulatory consideration of ADCs, and it summarizes the approved products in the market and in clinical trials.

Original languageEnglish
Pages (from-to)1177-1193
Number of pages17
JournalPolymers for Advanced Technologies
Issue number6
StatePublished - 1 Jun 2020
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2019 John Wiley & Sons, Ltd.


  • antibody drug conjugates
  • cytotoxicity
  • monoclonal antibody
  • synthesis


Dive into the research topics of 'Antibody drug conjugates: Development, characterization, and regulatory considerations'. Together they form a unique fingerprint.

Cite this